Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort

Korchia, Théo; Faugere, Mélanie; Suc, Nicolas; Garosi, Alexandra; Andrieu-Haller, C.; Breyton, Martin; Godin, O.; Aouizerate, Bruno; Arbus, Christophe; Bennabi, Djamila; Bellivierid, Frank; Bougerol, Thierry; Camus, Vincent; Courtet, Philippe; Doumy, Olivier; El‐Hage, Wissam; Genty, Jean-Baptiste; Haffen, Emmanuel; Holtzmann, Jérôme; Hörn, M.; Leboyer, Marion; Llorca, Pierre‐Michel; Maruani, Julia; Moirand, Rémi; Molière, Fanny; Petrucci, J.; Rey, Romain; Samalin, Ludovic; Stéphan, Florian; Vaïva, Guillaume; Walter, Michel; Yrondid, Antoine; Boyers, Laurent; Lançon, Christophe; Richieri, Raphaëlle; Fond, Guillaume

doi:10.1016/j.pnpbp.2021.110479

Cited by 7 publications

(5 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, our study revealed a significant relationship between habitual smoking behavior and patients with MDD who have TRD. This finding is consistent with previous research [ 52 , 53 ]. In the study by Korchia et al (2022) conducted on French cohorts of severe psychiatric disorders, tobacco smoking was associated with unfavorable outcomes in TRD, particularly in women.…”

Section: Discussionsupporting

confidence: 94%

The prevalence and economic burden of treatment-resistant depression in Thailand

Prasartpornsirichoke,

Pityaratstian,

Poolvoralaks

et al. 2023

BMC Public Health

View full text Add to dashboard Cite

Background The objectives of this study were to investigate the proportion of treatment-resistant depression (TRD) among patients with diagnosed major depressive disorder (MDD) and undergoing antidepressant treatment, to estimate the economic cost of MDD, TRD, and non-treatment-resistant depression (non-TRD), and to examine the differences between TRD and non-TRD MDD in a Thai public tertiary hospital. Methods This was a combined study between retrospective review of medical records and a cross-sectional survey. The sample size was 500 dyads of antidepressant-treated MDD patients and their unpaid caregivers. MDD patients’ medical records, the concept of healthcare resource utilization, the Work Productivity and Activity Impairment Questionnaire: depression and mood & mental state versions (WPAI: D, MM), the Class Impairment Questionnaire (CIQ), and the Family Experiences Interview Schedule (FEIS) were applied as the tools of the study. Pearson Chi’s square, Fisher’s Exact test, and independent T-test were employed for statistical analysis. Results The proportion of TRD was 19.6% among antidepressant-treated MDD patients in a Thai tertiary public hospital. The results of the study indicated that several factors showed a statistically significant association with TRD criteria. These factors included younger age of MDD patients, a younger age of onset of MDD, lower body mass index (BMI), a history of suicide attempts and self-harm, as well as frequent smoking behavior. The annualized economic cost of TRD was 276,059.97 baht per person ($7,668.33), which was significantly higher than that of cost of non-TRD (173,487.04 baht or $4,819.08). The aggregated economic costs of MDD were 96.8 million baht annually ($2.69 M) if calculated from 500 MDD patients and unpaid caregivers. This contributed to the economic cost of TRD 27.05 million baht (98 respondents) and the economic cost of non-TRD 69.74 million baht (402 respondents). Conclusions The economic burden associated with TRD was significantly higher compared to non-TRD among antidepressant-treated MDD patients. Specifically, both direct medical costs and indirect costs were notably elevated in the TRD group.

show abstract

Section: Discussionsupporting

confidence: 94%

The prevalence and economic burden of treatment-resistant depression in Thailand

Prasartpornsirichoke,

Pityaratstian,

Poolvoralaks

et al. 2023

BMC Public Health

View full text Add to dashboard Cite

show abstract

“…Some epidemiological studies reported an increased risk of adverse psychiatric events associated with varenicline use, such as anxiety and depression. 22,23 However, in our study, only the incidence of depression was higher than the placebo group, consistent with the above epidemiological findings, whereas the incidence of anxiety was not increased.…”

Section: Discussionsupporting

confidence: 91%

Effectiveness and Safety of Varenicline for Smoking Cessation: An Overview and Meta-analysis

et al. 2023

View full text Add to dashboard Cite

Objective: An overview, meta-analysis, and trial sequential analysis were conducted to evaluate the efficacy and safety of varenicline for smoking cessation. Methods: Systematic reviews (SRs) and randomized controlled trials evaluating varenicline versus placebo for smoking cessation were included. A forest plot was used to summarize the effect size of the included SRs. Traditional meta-analysis and trial sequential analysis (TSA) were performed using Stata software and TSA 0.9 software, respectively. Finally, the Grades of Recommendation, Assessment, Development, and Evaluation approach was used to assess the quality of evidence for the abstinence effect. Results: A total of 13 SRs and 46 randomized controlled trials were included. Twelve review studies showed that varenicline was superior to placebo for smoking cessation. The meta-analysis results showed that, compared with the placebo, varenicline significantly increased the odds of smoking cessation (odds ratio = 2.54, 95% confidence interval = 2.20-2.94, P < 0.05, moderate quality). Subgroup analysis showed that there were significant differences in smokers with disease and general smokers ( P < 0.05). Differences were also found in the follow-up time at 12, 24, and 52 weeks ( P < 0.05). The common adverse events were nausea, vomit, abnormal dreams, sleep disturbances, headache, depression, irritability, indigestion, and nasopharyngitis ( P < 0.05). The TSA results confirmed the evidence for the effect of varenicline on smoking cessation.Conclusions: Existing evidence supports the superiority of varenicline over a placebo for smoking cessation. Varenicline had mild to moderate adverse events but was well tolerated. Future trials should investigate varenicline in combination with other smoking cessation approaches and compare it with other interventions.

show abstract

“…Smokers normally use certain drugs such as anxiolytics; there is a well-known close relationship between smoking and psychiatric disorders (a higher proportion of subjects with mental health disorders smoke, when compared to general population). Women smokers are a specific population with more severe mental health outcomes that need to be specifically addressed ( 37 ).…”

Section: Discussionmentioning

confidence: 99%

Benzodiazepines and Z-hypnotics consumption in long-COVID-19 patients: Gender differences and associated factors

Carrasco‐Garrido

Fernández‐de‐las‐Peñas

Hernández‐Barrera

et al. 2022

Front. Med.

View full text Add to dashboard Cite

BackgroundPsychotropic drug consumption has increased during the COVID-19 pandemic. We describe here the prevalence and identifying factors associated with Benzodiazepine (BZD) and Z-hypnotics use among a sample of Spanish adults suffering from long-COVID-19 syndrome, from a gender perspective.Materials and methodsData were anonymously collected between 15th December 2021 and 15th March 2022. The collection form consisted of several questions gathering sociodemographic information, post-COVID symptom, health profile, and pharmacological drug intake. Using logistic multivariate regression models, we estimated the independent effect of each of these variables on self-medicated consumption. Three models were generated (female, male, and both gender).ResultsPrevalence of BZD and Z-hypnotics use was 44.9% (46.5% for women; 37.8% for men). Zolpidem was the most consumed drug among male (20.7%), and lorazepam in female (31.1%). Patterns of drug consumption among female were related with number of post-COVID symptoms and smoking habit (AOR 2.76, 95%CI 1.16–6.52). Males under 40 years of age are more likely to consume BZD and Z-hypnotics (AOR 5.52, 95%CI 1.08–28.27).ConclusionThe prevalence of consumption of BZD and Z-hypnotics in those subjects with long-COVID-19 in our study reaches values of 44.9%. Women with long-COVID-19 declare a higher prevalence of consumption than men. Predictors of BZD and Z-hypnotic in men were, age and number of medication use. Smoking habit and the number of post-COVID symptoms were predictive variables in women.

show abstract

Recommendations of the treatment-resistant depression expert center network for promoting tobacco smoking cessation based on the results from the real-world FACE-TRD national cohort

Cited by 7 publications

References 68 publications

The prevalence and economic burden of treatment-resistant depression in Thailand

The prevalence and economic burden of treatment-resistant depression in Thailand

Effectiveness and Safety of Varenicline for Smoking Cessation: An Overview and Meta-analysis

Benzodiazepines and Z-hypnotics consumption in long-COVID-19 patients: Gender differences and associated factors

Contact Info

Product

Resources

About